Identification

Name
Quetiapine
Accession Number
DB01224  (APRD00675)
Type
Small Molecule
Groups
Approved
Description

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

Structure
Thumb
Synonyms
  • 2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
  • Quetiapina
  • Quetiapine
  • Quetiapine fumarate
  • Quetiapine hemifumarate
  • Quetiapinum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-quetiapineTablet, multilayer, extended release200 mgOralBgp Pharma Ulc2014-06-132015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release25 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release300 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release100 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Accel-quetiapineTablet25 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet300 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet200 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet100 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet150 mgOralAccel Pharma Inc2015-03-032017-01-27Canada
Ach-quetiapine Fumarate XRTablet, extended release300 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quetiapineTablet200 mgOralApotex Corporation2008-09-04Not applicableCanada
Apo-quetiapineTablet25 mgOralApotex Corporation2008-09-04Not applicableCanada
Apo-quetiapineTablet300 mgOralApotex Corporation2008-09-04Not applicableCanada
Apo-quetiapineTablet100 mgOralApotex Corporation2008-09-04Not applicableCanada
Apo-quetiapine XRTablet, extended release200 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release50 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release300 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release150 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release400 mgOralApotex CorporationNot applicableNot applicableCanada
QuetiapineTablet, film coated400 mg/1OralTeva2012-03-27Not applicableUs
Categories
UNII
BGL0JSY5SI
CAS number
111974-69-7
Weight
Average: 383.507
Monoisotopic: 383.166747749
Chemical Formula
C21H25N3O2S
InChI Key
URKOMYMAXPYINW-UHFFFAOYSA-N
InChI
InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
IUPAC Name
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol
SMILES
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12

Pharmacology

Indication

For the treatment of schizophrenia and related psychotic disorders.

Structured Indications
Pharmacodynamics

Quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT1A and 5HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Mechanism of action

Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
other/unknown
Human
U5-hydroxytryptamine receptor 1D
other/unknown
Human
U5-hydroxytryptamine receptor 1E
other/unknown
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
other/unknown
Human
U5-hydroxytryptamine receptor 6
other/unknown
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(1B) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

Rapidly and well absorbed.

Volume of distribution
  • 10±4 L/kg
Protein binding

83%

Metabolism

Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy- N-delakylated metabolites appear to be active, but are present in very low concentrations.

Route of elimination

Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.

Half life

6 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Quetiapine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Quetiapine.Investigational
2,5-Dimethoxy-4-ethylamphetamineQuetiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineQuetiapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Quetiapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Quetiapine.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Quetiapine can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quetiapine.Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Quetiapine can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Quetiapine.Experimental
AlaproclateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Quetiapine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.Approved
AldosteroneThe serum concentration of Quetiapine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Quetiapine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Quetiapine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Quetiapine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Quetiapine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quetiapine.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Quetiapine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Quetiapine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quetiapine.Approved
Aminohippuric acidThe serum concentration of Quetiapine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Quetiapine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quetiapine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Quetiapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amperozide.Experimental
AmphetamineQuetiapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Quetiapine.Approved, Investigational
AmprenavirThe serum concentration of Quetiapine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Quetiapine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Quetiapine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Quetiapine.Approved
AprepitantThe serum concentration of Quetiapine can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Quetiapine.Approved, Investigational
ArmodafinilThe metabolism of Quetiapine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Quetiapine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Quetiapine.Approved, Investigational
ArtemetherThe metabolism of Quetiapine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Asenapine.Approved
AstemizoleThe serum concentration of Quetiapine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Quetiapine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Quetiapine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
AtorvastatinThe serum concentration of Quetiapine can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azaperone.Vet Approved
AzelastineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Quetiapine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Quetiapine.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Quetiapine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Quetiapine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Quetiapine.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Quetiapine.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quetiapine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Quetiapine can be increased when it is combined with Benzocaine.Approved
BenzphetamineQuetiapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Quetiapine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quetiapine.Approved
BiperidenThe serum concentration of Quetiapine can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quetiapine.Approved
BoceprevirThe serum concentration of Quetiapine can be increased when it is combined with Boceprevir.Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
BosentanThe serum concentration of Quetiapine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Quetiapine can be increased when it is combined with Bosutinib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Quetiapine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quetiapine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Quetiapine.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bupivacaine.Approved, Investigational
BuprenorphineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Quetiapine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Quetiapine.Approved
BuspironeThe serum concentration of Quetiapine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quetiapine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Quetiapine can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quetiapine.Approved
CaffeineThe serum concentration of Quetiapine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Quetiapine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Quetiapine is combined with Canertinib.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.Approved
CarbamazepineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Quetiapine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Quetiapine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Quetiapine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Quetiapine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Quetiapine.Approved, Investigational
CaspofunginThe serum concentration of Quetiapine can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quetiapine.Experimental
CelecoxibThe metabolism of Quetiapine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Quetiapine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Quetiapine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quetiapine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Quetiapine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorphenamine.Approved
ChlorphentermineQuetiapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quetiapine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Quetiapine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Quetiapine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quetiapine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Quetiapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Quetiapine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Quetiapine can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quetiapine.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Quetiapine.Approved
CimetidineThe serum concentration of Quetiapine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Quetiapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Quetiapine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Quetiapine can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Quetiapine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Quetiapine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clidinium.Approved
ClobazamThe metabolism of Quetiapine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Quetiapine.Approved, Investigational
ClofazimineThe serum concentration of Quetiapine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Quetiapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quetiapine.Approved
CobicistatThe serum concentration of Quetiapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Quetiapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quetiapine.Approved, Illicit
ColchicineThe serum concentration of Quetiapine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Quetiapine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Quetiapine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Quetiapine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.Approved
CyclophosphamideThe serum concentration of Quetiapine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Quetiapine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Quetiapine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Quetiapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Quetiapine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Quetiapine can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Quetiapine.Approved
DelavirdineThe metabolism of Quetiapine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Quetiapine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Quetiapine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Quetiapine.Approved
DesloratadineThe serum concentration of Quetiapine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Quetiapine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quetiapine.Approved, Vet Approved
DextroamphetamineQuetiapine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Quetiapine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Quetiapine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Quetiapine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Quetiapine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Quetiapine is combined with Diethyl ether.Experimental
DiethylpropionQuetiapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Quetiapine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Quetiapine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Quetiapine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Quetiapine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quetiapine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Quetiapine.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Quetiapine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dixyrazine.Experimental
DofetilideDofetilide may increase the QTc-prolonging activities of Quetiapine.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Quetiapine.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Quetiapine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Quetiapine.Approved
DoxorubicinThe serum concentration of Quetiapine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Quetiapine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Quetiapine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Illicit
DronedaroneThe metabolism of Quetiapine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quetiapine.Approved
DuloxetineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Quetiapine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Quetiapine.Approved
ElbasvirThe serum concentration of Quetiapine can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Quetiapine.Approved, Investigational
EliglustatThe metabolism of Quetiapine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quetiapine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Quetiapine.Approved
EnasidenibThe serum concentration of Quetiapine can be increased when it is combined with Enasidenib.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Quetiapine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Quetiapine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.Approved
ErgonovineThe serum concentration of Quetiapine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Quetiapine can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ErythromycinThe metabolism of Quetiapine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Quetiapine.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Quetiapine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quetiapine.Approved
EsomeprazoleThe metabolism of Quetiapine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quetiapine.Approved, Illicit
EstramustineThe serum concentration of Quetiapine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Quetiapine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Quetiapine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quetiapine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.Approved
EthanolQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Quetiapine can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Quetiapine can be increased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Quetiapine.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Quetiapine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Quetiapine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Quetiapine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Quetiapine.Approved
FentanylThe serum concentration of Quetiapine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.Approved
FexofenadineThe serum concentration of Quetiapine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Quetiapine can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Quetiapine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Quetiapine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Quetiapine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Quetiapine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Quetiapine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Quetiapine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Quetiapine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Quetiapine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
FosamprenavirThe metabolism of Quetiapine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Quetiapine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Quetiapine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.Approved
FosphenytoinThe serum concentration of Quetiapine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Quetiapine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Quetiapine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quetiapine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gabapentin Enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Quetiapine.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Quetiapine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Quetiapine can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Quetiapine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GenisteinThe serum concentration of Quetiapine can be increased when it is combined with Genistein.Investigational
GepefrineQuetiapine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gepirone.Investigational
GlecaprevirThe serum concentration of Quetiapine can be increased when it is combined with Glecaprevir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quetiapine.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Quetiapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quetiapine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quetiapine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Quetiapine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Quetiapine can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Quetiapine.Approved
Gramicidin DThe serum concentration of Quetiapine can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GrepafloxacinThe serum concentration of Quetiapine can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Quetiapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Quetiapine can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Quetiapine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Quetiapine.Approved, Vet Approved
HydrocodoneQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Quetiapine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Quetiapine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.Approved, Illicit
HydroxyamphetamineQuetiapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Quetiapine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Quetiapine.Approved, Investigational
ImatinibThe metabolism of Quetiapine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Quetiapine.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Quetiapine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Quetiapine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Quetiapine.Approved
IndinavirThe serum concentration of Quetiapine can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Quetiapine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Quetiapine.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quetiapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Quetiapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quetiapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Quetiapine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Quetiapine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quetiapine.Approved
Iofetamine I-123Quetiapine may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.Approved, Investigational
IsavuconazoniumThe metabolism of Quetiapine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Quetiapine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
IsoniazidThe metabolism of Quetiapine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Quetiapine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Quetiapine.Approved
ItraconazoleThe serum concentration of Quetiapine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Quetiapine.Approved
IvacaftorThe serum concentration of Quetiapine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Quetiapine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Quetiapine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Quetiapine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Quetiapine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Quetiapine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Quetiapine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Quetiapine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Quetiapine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocetirizine.Approved
LevodopaQuetiapine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Quetiapine can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Quetiapine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quetiapine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Quetiapine.Approved, Investigational
LevothyroxineThe serum concentration of Quetiapine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Quetiapine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Quetiapine.Approved, Investigational
LiothyronineThe serum concentration of Quetiapine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Quetiapine can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Quetiapine.Approved
LisdexamfetamineQuetiapine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Quetiapine.Approved
LobeglitazoneThe metabolism of Quetiapine can be decreased when combined with Lobeglitazone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Quetiapine.Approved, Investigational
LomitapideThe serum concentration of Quetiapine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Quetiapine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Quetiapine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Quetiapine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quetiapine.Approved
LorcaserinThe metabolism of Quetiapine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.Approved
LovastatinThe metabolism of Quetiapine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quetiapine.Approved
LuliconazoleThe serum concentration of Quetiapine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Quetiapine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Quetiapine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
ManidipineThe metabolism of Quetiapine can be decreased when combined with Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Quetiapine.Approved
MebendazoleThe serum concentration of Quetiapine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Quetiapine.Approved
Megestrol acetateThe serum concentration of Quetiapine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Quetiapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Melperone.Approved
MephedroneQuetiapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineQuetiapine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Quetiapine can be increased when it is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meptazinol.Experimental
MequitazineQuetiapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Quetiapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineQuetiapine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quetiapine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Quetiapine.Approved
MethotrimeprazineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineQuetiapine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Quetiapine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Quetiapine.Approved
MetyrosineQuetiapine may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Quetiapine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Quetiapine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Quetiapine can be decreased when it is combined with Midazolam.Approved, Illicit
MidomafetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MidostaurinThe metabolism of Quetiapine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Quetiapine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quetiapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Quetiapine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Quetiapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quetiapine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Quetiapine.Approved
MirtazapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
MitomycinThe serum concentration of Quetiapine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Quetiapine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Quetiapine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAQuetiapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Quetiapine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Quetiapine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Quetiapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Molindone.Approved
MorphineThe serum concentration of Quetiapine can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Quetiapine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Quetiapine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quetiapine.Approved
NaltrexoneThe serum concentration of Quetiapine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Quetiapine.Approved, Investigational
NaringeninThe serum concentration of Quetiapine can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Quetiapine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Quetiapine can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Quetiapine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Quetiapine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Quetiapine can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Quetiapine.Approved
NicorandilNicorandil may increase the hypotensive activities of Quetiapine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.Approved
NilotinibThe metabolism of Quetiapine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Quetiapine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.Approved
NitrazepamThe serum concentration of Quetiapine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Quetiapine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Quetiapine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quetiapine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quetiapine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrous oxide.Approved, Vet Approved
NorethisteroneThe serum concentration of Quetiapine can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Quetiapine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
OlaparibThe metabolism of Quetiapine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quetiapine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Quetiapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Quetiapine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Opium.Approved, Illicit
OrphenadrineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Quetiapine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quetiapine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quetiapine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
P-NitrophenolThe serum concentration of Quetiapine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Quetiapine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Quetiapine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Quetiapine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Quetiapine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.Approved
ParaldehydeQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Quetiapine.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Quetiapine.Approved
Peginterferon alfa-2bThe serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Quetiapine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.Approved, Vet Approved
PentobarbitalThe serum concentration of Quetiapine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Quetiapine.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quetiapine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quetiapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quetiapine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Quetiapine.Approved, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenibut.Experimental
PhenobarbitalThe serum concentration of Quetiapine can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Quetiapine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoxyethanol.Approved
PhentermineQuetiapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Quetiapine.Approved
PhenytoinThe serum concentration of Quetiapine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Quetiapine can be increased when it is combined with Pibrentasvir.Approved
PimozideThe serum concentration of Quetiapine can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Quetiapine.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quetiapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Quetiapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Quetiapine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Quetiapine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Quetiapine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleQuetiapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Quetiapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Quetiapine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Quetiapine.Approved
PrednisoneThe serum concentration of Quetiapine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quetiapine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Quetiapine.Approved
PrimidoneThe serum concentration of Quetiapine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Quetiapine can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Quetiapine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Quetiapine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.Approved, Vet Approved
ProgesteroneThe serum concentration of Quetiapine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Quetiapine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Quetiapine.Approved
PropafenoneThe serum concentration of Quetiapine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Quetiapine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Quetiapine.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Quetiapine is combined with PSD502.Investigational
PseudoephedrineQuetiapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Quetiapine can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Quetiapine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.Approved, Investigational
QuinidineThe metabolism of Quetiapine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quetiapine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quetiapine.Approved
RanitidineThe serum concentration of Quetiapine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Quetiapine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.Approved
ReboxetineThe serum concentration of Quetiapine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Quetiapine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quetiapine.Approved
RifabutinThe serum concentration of Quetiapine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Quetiapine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Quetiapine can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Quetiapine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Quetiapine is combined with Riociguat.Approved
RisperidoneQuetiapine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ritanserin.Investigational
RitobegronQuetiapine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Quetiapine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Quetiapine.Approved
RolapitantThe serum concentration of Quetiapine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Romifidine.Vet Approved
RopiniroleQuetiapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quetiapine.Approved, Investigational
RotigotineQuetiapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Quetiapine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Quetiapine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Quetiapine.Approved
SaquinavirThe serum concentration of Quetiapine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quetiapine.Approved
ScopolamineThe serum concentration of Quetiapine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quetiapine.Approved, Vet Approved
SelegilineThe serum concentration of Quetiapine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Quetiapine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SildenafilThe metabolism of Quetiapine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Quetiapine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Quetiapine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Quetiapine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Quetiapine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quetiapine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Quetiapine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Quetiapine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Quetiapine.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Quetiapine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.Approved
St. John's WortQuetiapine may increase the serotonergic activities of St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Quetiapine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Quetiapine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Quetiapine.Approved
StreptozocinThe serum concentration of Quetiapine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Quetiapine.Approved
SulfinpyrazoneThe serum concentration of Quetiapine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Quetiapine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quetiapine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Quetiapine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
SuvorexantQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Quetiapine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Quetiapine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Quetiapine.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Quetiapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Quetiapine can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Quetiapine.Approved
TelaprevirThe serum concentration of Quetiapine can be increased when it is combined with Telaprevir.Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Quetiapine.Approved
TelithromycinThe serum concentration of Quetiapine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Quetiapine.Approved
TemsirolimusThe serum concentration of Quetiapine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Quetiapine.Approved
TerbinafineThe metabolism of Quetiapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Quetiapine.Approved
TerfenadineThe serum concentration of Quetiapine can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Quetiapine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Quetiapine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Quetiapine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrodotoxin.Investigational
ThalidomideQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quetiapine.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Quetiapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Quetiapine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Quetiapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Quetiapine.Approved
TipranavirThe metabolism of Quetiapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Quetiapine.Approved
TocilizumabThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quetiapine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Quetiapine.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quetiapine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TolvaptanThe serum concentration of Quetiapine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quetiapine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Quetiapine can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Quetiapine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quetiapine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trichloroethylene.Experimental
TrifluoperazineThe serum concentration of Quetiapine can be increased when it is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trifluperidol.Experimental
TriflupromazineThe serum concentration of Quetiapine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Quetiapine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Quetiapine.Withdrawn
TroleandomycinThe serum concentration of Quetiapine can be increased when it is combined with Troleandomycin.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Quetiapine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.Approved, Investigational
VandetanibQuetiapine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Quetiapine.Approved
VelpatasvirThe serum concentration of Quetiapine can be increased when it is combined with Velpatasvir.Approved
VemurafenibQuetiapine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Quetiapine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quetiapine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Quetiapine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Quetiapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quetiapine.Approved, Investigational
VinblastineThe serum concentration of Quetiapine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Quetiapine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Quetiapine can be increased when it is combined with Vinorelbine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Quetiapine.Approved, Investigational
VoriconazoleThe serum concentration of Quetiapine can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Quetiapine can be increased when it is combined with Voxilaprevir.Approved
XenonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quetiapine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Quetiapine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Quetiapine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quetiapine.Approved, Investigational
ZolpidemQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Quetiapine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zotepine.Approved
ZucapsaicinThe metabolism of Quetiapine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference
US4879288
General References
  1. Dev V, Raniwalla J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf. 2000 Oct;23(4):295-307. [PubMed:11051217]
  2. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. [PubMed:14642017]
  3. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P: Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5. [PubMed:11245917]
  4. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
External Links
Human Metabolome Database
HMDB05021
KEGG Compound
C07397
PubChem Compound
5002
PubChem Substance
46504800
ChemSpider
4827
BindingDB
50095890
ChEBI
8707
ChEMBL
CHEMBL716
Therapeutic Targets Database
DAP000001
PharmGKB
PA451201
IUPHAR
50
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Quetiapine
ATC Codes
N05AH04 — Quetiapine
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (273 KB)
MSDS
Download (57.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedPreventionSocial Anxiety Disorder (SAD)1
0TerminatedTreatmentMethamphetamine Dependence1
1CompletedNot AvailableBipolar Disorder (BD)1
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceDepressive State1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentDyskinesia, Drug-Induced1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers3
1RecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1RecruitingTreatmentSchizophrenic Disorders1
1Unknown StatusTreatmentCocaine-Related Disorders1
1Unknown StatusTreatmentHealthy Volunteers1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2TerminatedTreatmentDelirium1
2Active Not RecruitingTreatmentCannabis Dependence1
2CompletedNot AvailableSpecific Phobias1
2CompletedBasic ScienceSmoking, Marijuana1
2CompletedTreatmentAlcohol Abuse / Alcohol Consumption / Alcohol Drinking / Alcohol Relapse Prevention / Alcoholism1
2CompletedTreatmentAlcohol Abuse / Alcoholism1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentBorderline Personality Disorder (BPD)1
2CompletedTreatmentCannabis Dependence1
2CompletedTreatmentDepression, Bipolar1
2CompletedTreatmentMajor Depressive Disorder (MDD)2
2CompletedTreatmentObsessive Compulsive Disorder (OCD)1
2TerminatedTreatmentAnorexia Nervosa (AN)1
2TerminatedTreatmentBipolar Disorder (BD)1
2TerminatedTreatmentDepression in Patients With Bipolar Disorder1
2TerminatedTreatmentNicotine Dependence / Nicotine Use Disorder / Smoking / Tobacco Use Disorders1
2TerminatedTreatmentPostpartum Depressive Disorder1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2WithdrawnTreatmentMajor Depressive Disorder (MDD)1
2, 3CompletedTreatmentBipolar Disorder (BD)1
2, 3CompletedTreatmentBipolar II Disorder1
2, 3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2, 3CompletedTreatmentSleeplessness1
2, 3CompletedTreatmentSocial Anxiety Disorder (SAD)1
2, 3TerminatedTreatmentSchizophrenic Disorders1
3CompletedNot AvailableBipolar Disorder (BD)1
3CompletedPreventionBipolar I Disorder1
3CompletedTreatmentAcute Bipolar Depression1
3CompletedTreatmentAlcohol Dependence / Bipolar I Disorder1
3CompletedTreatmentAlcoholism1
3CompletedTreatmentAlcoholism / Sleep Initiation and Maintenance Disorders1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular1
3CompletedTreatmentAnxiety Disorders1
3CompletedTreatmentAnxiety Disorders / Anxiety States / Feeling Anxious / Neuroses, Anxiety1
3CompletedTreatmentAnxiety Disorders / Bipolar Disorder (BD) / Feeling Anxious / Substance Use Disorder (SUD)1
3CompletedTreatmentBipolar Disorder (BD)6
3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar2
3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar / Depressive State1
3CompletedTreatmentBipolar Disorder (BD) / Elderly1
3CompletedTreatmentBipolar Disorder (BD) / Mania1
3CompletedTreatmentBipolar Disorder (BD) / Moods Disorders1
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar I Disorder1
3CompletedTreatmentBipolar I Disorder / Schizophrenic Disorders1
3CompletedTreatmentBorderline Personality Disorder (BPD)2
3CompletedTreatmentChronic Schizophrenia1
3CompletedTreatmentCognition / Schizophrenic Disorders1
3CompletedTreatmentDepression, Bipolar3
3CompletedTreatmentDepressive Disorders / Depressive State / Major Depressive Disorder (MDD) / Moods Disorders / Psychiatric Disorder NOS1
3CompletedTreatmentDepressive State / Schizophrenic Disorders1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)3
3CompletedTreatmentMajor Depressive Disorder (MDD)7
3CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
3CompletedTreatmentMoods Disorders1
3CompletedTreatmentObsessive Compulsive Disorder (OCD)1
3CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
3CompletedTreatmentPsychosis1
3CompletedTreatmentPsychotic Depression1
3CompletedTreatmentPsychotic Disorder NOS1
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders12
3CompletedTreatmentSleep1
3CompletedTreatmentSocial Anxiety Disorder (SAD)1
3CompletedTreatmentUnipolar Depression1
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3RecruitingTreatmentBipolar Youth Treated With Second-generation Antipsychotics1
3RecruitingTreatmentMajor Depressive Disorder (MDD)1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3TerminatedTreatmentAcute Agitation / Dementias1
3TerminatedTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS / Schizophrenic Disorders1
3TerminatedTreatmentDelirium1
3TerminatedTreatmentDepression With Prominent Agitation1
3TerminatedTreatmentGeneralized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
3TerminatedTreatmentMajor Depression With Psychotic Features1
3TerminatedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentSchizophrenic Disorders6
3TerminatedTreatmentSocial Anxiety Disorder (SAD)1
3Unknown StatusPreventionDelirium1
3Unknown StatusTreatmentBipolar Disorder (BD)1
3Unknown StatusTreatmentDelirium1
3Unknown StatusTreatmentFeeling Anxious / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentBipolar Disorder (BD)1
4Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedNot AvailableAlcohol Abuse / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Substance Abuse1
4CompletedNot AvailableBipolar Disorder (BD)1
4CompletedNot AvailableDepression, Bipolar1
4CompletedNot AvailableMajor Depressive Disorder (MDD)1
4CompletedNot AvailableSchizophrenic Disorders2
4CompletedNot AvailableSchizophrenic Disorders / Substance Use Disorder (SUD)1
4CompletedDiagnosticSchizophrenic Disorders1
4CompletedPreventionSchizophrenic Disorders1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentAcute Mania1
4CompletedTreatmentAcute Mania in Bipolar Disorder1
4CompletedTreatmentAlcohol Abuse/Dependence / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Abuse / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Dependence / Bipolar Disorder (BD)1
4CompletedTreatmentAlcoholism / Anxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Alzheimer Type / Dementias / Senile Dementia, Alzheimer Type1
4CompletedTreatmentAnxiety Disorders1
4CompletedTreatmentBipolar Affective Psychosis / Bipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes1
4CompletedTreatmentBipolar Disorder (BD)4
4CompletedTreatmentBipolar Disorder (BD) / Cannabis-Related Disorder1
4CompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar I Disorder / Bipolar II Disorder1
4CompletedTreatmentBipolar II Disorder1
4CompletedTreatmentBipolar Spectrum Disorder1
4CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders1
4CompletedTreatmentCombat Disorders / Stress Disorders, Post-Traumatic1
4CompletedTreatmentDementias / Parkinson's Disease (PD)1
4CompletedTreatmentDepressive State1
4CompletedTreatmentDepressive State / Feeling Anxious1
4CompletedTreatmentDepressive State / Healthy Volunteers1
4CompletedTreatmentFibromyalgia3
4CompletedTreatmentHyperglycemias / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentMajor Depression With Comorbid Anxiety Symptoms1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentMajor Depressive Disorder (MDD) / Menopausal Hot Flushes / Sleeplessness1
4CompletedTreatmentMood Disorders With Comorbid Anxiety Symptoms / Primary Anxiety Disorders1
4CompletedTreatmentObsessive Compulsive Disorder (OCD)2
4CompletedTreatmentPTSD1
4CompletedTreatmentPanic Disorders1
4CompletedTreatmentPsychomotor Agitation1
4CompletedTreatmentPsychotic Disorder NOS2
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders3
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders5
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Substance Abuse / Substance Dependence1
4CompletedTreatmentSchizophrenic Disorders17
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentSocial Anxiety Disorder (SAD)1
4CompletedTreatmentSocial Phobia1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingTreatmentBipolar Disorder (BD)2
4RecruitingTreatmentBipolar Disorder (BD) / Substance Use Disorder (SUD)1
4RecruitingTreatmentDepressive Disorder, Treatment-Resistant1
4RecruitingTreatmentSchizophrenic Disorders1
4TerminatedNot AvailableHigh Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure1
4TerminatedTreatmentAcute Bipolar Mania2
4TerminatedTreatmentBipolar Disorder (BD)2
4TerminatedTreatmentBipolar Disorder (BD) / Cognitive Impairments1
4TerminatedTreatmentComorbid Opiate Dependence in Remission / Generalized Anxiety Disorder (GAD) / Status Post Methadone-Maintenance Treatment1
4TerminatedTreatmentGeneralized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
4TerminatedTreatmentMajor Depressive Disorder With Psychotic Features1
4TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4TerminatedTreatmentSchizophrenic Disorders1
4Unknown StatusBasic ScienceDepression, Bipolar1
4Unknown StatusTreatmentAbnormal Mental State / Schizophrenic Disorders1
4Unknown StatusTreatmentAcute Schizophrenia1
4Unknown StatusTreatmentBipolar Disorder (BD)1
4Unknown StatusTreatmentBipolar, Mania / Seroquel / Utapine1
4Unknown StatusTreatmentBipolar / Schizophrenic Disorders1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMental Health Disorder / Sleeplessness / Substance Use Disorder (SUD)1
4Unknown StatusTreatmentPsychosis1
4Unknown StatusTreatmentPsychosis / Schizophrenic Disorders1
4Unknown StatusTreatmentSchizophrenia or Schizoaffective Disorder1
4Unknown StatusTreatmentSchizophrenic Disorders1
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentAlzheimer's Disease (AD) / Behavioral Symptoms / Dementias1
4WithdrawnTreatmentDepression, Bipolar1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Metabolic Syndromes / Psychotic Disorder NOS1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDelirium / Dementias1
Not AvailableCompletedNot AvailableSchizophrenic Disorders1
Not AvailableCompletedDiagnosticBipolar Disorder (BD) / Mania1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAnxiety Disorders / Dysthymic Disorder / Generalized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine / Methamphetamine Dependence1
Not AvailableCompletedTreatmentBipolar I Disorder2
Not AvailableCompletedTreatmentCocaine Abuse / Dependence, Cocaine / Drug Abuse / Substance Abuse1
Not AvailableCompletedTreatmentFunctional Bowel Disorders1
Not AvailableCompletedTreatmentGeneralized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
Not AvailableCompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
Not AvailableCompletedTreatmentPostpartum Depression1
Not AvailableCompletedTreatmentPrimary Insomnia1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableCompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders3
Not AvailableCompletedTreatmentTreatment for Bipolar I Disorder1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingBasic ScienceBipolar Disorder (BD) / Depressive State1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)2
Not AvailableRecruitingNot AvailableMicrognathia / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders2
Not AvailableTerminatedTreatmentGeneralized Anxiety Disorder (GAD) / Seroquel XR1
Not AvailableUnknown StatusNot AvailableDissociative Disorders1
Not AvailableUnknown StatusEducational/Counseling/TrainingSmoking Behavior in Schizophrenia1
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusTreatmentAlzheimer's Disease (AD) / Sleeplessness1
Not AvailableUnknown StatusTreatmentAnorexia Nervosa (AN)1
Not AvailableUnknown StatusTreatmentBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, multilayer, extended releaseOral100 mg
Tablet, multilayer, extended releaseOral200 mg
Tablet, multilayer, extended releaseOral25 mg
Tablet, multilayer, extended releaseOral300 mg
TabletOral50 mg
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral25 mg/1
TabletOral300 mg/1
TabletOral400 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coated, extended releaseOral150 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Tablet, film coated, extended releaseOral400 mg/1
Tablet, film coated, extended releaseOral50 mg/1
TabletOral300 mg
TabletOral100 mg
TabletOral200 mg
TabletOral25 mg
Kit
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral150 mg/1
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral300 mg
Tablet, extended releaseOral400 mg/1
Tablet, extended releaseOral400 mg
Tablet, extended releaseOral50 mg/1
Tablet, extended releaseOral50 mg
TabletOral150 mg
Prices
Unit descriptionCostUnit
Seroquel 400 mg tablet16.71USD tablet
Seroquel xr 400 mg tablet14.82USD tablet
Seroquel 300 mg tablet14.21USD tablet
Seroquel xr 300 mg tablet12.61USD tablet
Seroquel 200 mg tablet10.84USD tablet
SEROquel XR 200 mg 24 Hour tablet10.0USD tablet
Seroquel xr 200 mg tablet9.62USD tablet
SEROquel XR 150 mg 24 Hour tablet9.09USD tablet
Seroquel xr 150 mg tablet8.74USD tablet
Seroquel 100 mg tablet5.75USD tablet
Seroquel 50 mg tablet5.5USD tablet
SEROquel XR 50 mg 24 Hour tablet5.06USD tablet
Seroquel xr 50 mg tablet4.87USD tablet
Seroquel 300 mg Tablet4.35USD tablet
Seroquel 25 mg tablet3.35USD tablet
Seroquel 200 mg Tablet2.98USD tablet
Apo-Quetiapine 300 mg Tablet2.44USD tablet
Co Quetiapine 300 mg Tablet2.44USD tablet
Jamp-Quetiapine 300 mg Tablet2.44USD tablet
Mylan-Quetiapine 300 mg Tablet2.44USD tablet
Novo-Quetiapine 300 mg Tablet2.44USD tablet
Pms-Quetiapine 300 mg Tablet2.44USD tablet
Ratio-Quetiapine 300 mg Tablet2.44USD tablet
Sandoz Quetiapine 300 mg Tablet2.44USD tablet
Apo-Quetiapine 200 mg Tablet1.67USD tablet
Co Quetiapine 200 mg Tablet1.67USD tablet
Jamp-Quetiapine 200 mg Tablet1.67USD tablet
Mylan-Quetiapine 200 mg Tablet1.67USD tablet
Novo-Quetiapine 200 mg Tablet1.67USD tablet
Pms-Quetiapine 200 mg Tablet1.67USD tablet
Ratio-Quetiapine 200 mg Tablet1.67USD tablet
Sandoz Quetiapine 200 mg Tablet1.67USD tablet
Seroquel 100 mg Tablet1.48USD tablet
Novo-Quetiapine 150 mg Tablet1.42USD tablet
Apo-Quetiapine 100 mg Tablet0.83USD tablet
Co Quetiapine 100 mg Tablet0.83USD tablet
Jamp-Quetiapine 100 mg Tablet0.83USD tablet
Mylan-Quetiapine 100 mg Tablet0.83USD tablet
Novo-Quetiapine 100 mg Tablet0.83USD tablet
Pms-Quetiapine 100 mg Tablet0.83USD tablet
Ratio-Quetiapine 100 mg Tablet0.83USD tablet
Sandoz Quetiapine 100 mg Tablet0.83USD tablet
Seroquel 25 mg Tablet0.56USD tablet
Apo-Quetiapine 25 mg Tablet0.31USD tablet
Co Quetiapine 25 mg Tablet0.31USD tablet
Jamp-Quetiapine 25 mg Tablet0.31USD tablet
Mylan-Quetiapine 25 mg Tablet0.31USD tablet
Novo-Quetiapine 25 mg Tablet0.31USD tablet
Pms-Quetiapine 25 mg Tablet0.31USD tablet
Ratio-Quetiapine 25 mg Tablet0.31USD tablet
Sandoz Quetiapine 25 mg Tablet0.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4879288No1994-09-262011-09-26Us
CA2251944No2007-04-102017-05-27Canada
US5948437Yes1997-11-282017-11-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityModerateNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.93ALOGPS
logP2.81ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)7.06ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity114.09 m3·mol-1ChemAxon
Polarizability42.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier+0.9906
Caco-2 permeable-0.6037
P-glycoprotein substrateSubstrate0.8424
P-glycoprotein inhibitor IInhibitor0.9117
P-glycoprotein inhibitor IIInhibitor0.9325
Renal organic cation transporterInhibitor0.5554
CYP450 2C9 substrateNon-substrate0.6438
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6049
CYP450 1A2 substrateInhibitor0.5744
CYP450 2C9 inhibitorNon-inhibitor0.6305
CYP450 2D6 inhibitorInhibitor0.588
CYP450 2C19 inhibitorNon-inhibitor0.7033
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5375
Ames testNon AMES toxic0.7479
CarcinogenicityNon-carcinogens0.869
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.8684
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , NegativeLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0089000000-b7b1c7d0bf6bb604c5cb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uk9-1390000000-ce855b6e08dee583681b

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzothiazepines. These are compounds containing a dibenzothiazepine moiety, which consists of two benzene connected by a thiazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazepines
Sub Class
Dibenzothiazepines
Direct Parent
Dibenzothiazepines
Alternative Parents
Diarylthioethers / N-alkylpiperazines / Imidolactams / Benzenoids / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Dialkyl ethers / Carboxamidines / Azacyclic compounds / Primary alcohols
show 2 more
Substituents
Dibenzothiazepine / Diarylthioether / Aryl thioether / N-alkylpiperazine / 1,4-diazinane / Piperazine / Benzenoid / Imidolactam / Tertiary amine / Tertiary aliphatic amine
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, N-alkylpiperazine, dibenzothiazepine (CHEBI:8707)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Goldstein JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999 Mar;35(3):193-210. [PubMed:12973385]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000 Jun;57(6):553-9. [PubMed:10839333]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  4. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  4. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1E
Uniprot ID
P28566
Uniprot Name
5-hydroxytryptamine receptor 1E
Molecular Weight
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
11. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
12. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
13. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
14. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
15. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
  2. DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-22. [PubMed:11510628]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13